68Ga prostate-specific membrane antigen positron emission tomography/computed tomography versus 99mTc methylene diphosphonate bone scintigraphy for detecting bone metastases in prostate cancer: The potential to replace the conventional modality
68Ga prostate-specific membrane antigen positron emission tomography/computed tomography versus 99mTc methylene diphosphonate bone scintigraphy for detecting bone metastases in prostate cancer: The potential to replace the conventional modality. // Asian Journal of Urology. – URL: https://www.sciencedirect.com/science/article/pii/S2214388226000822?dgcid=rss_sd_all
68Ga prostate-specific membrane antigen positron emission tomography/computed tomography versus 99mTc methylene diphosphonate bone scintigraphy for detecting bone metastases in prostate cancer: The potential to replace the conventional modality. Asian Journal of Urology. https://www.sciencedirect.com/science/article/pii/S2214388226000822?dgcid=rss_sd_all
“68Ga prostate-specific membrane antigen positron emission tomography/computed tomography versus 99mTc methylene diphosphonate bone scintigraphy for detecting bone metastases in prostate cancer: The potential to replace the conventional modality.” Asian Journal of Urology.
@article{article36916,
title = {68Ga prostate-specific membrane antigen positron emission tomography/computed tomography versus 99mTc methylene diphosphonate bone scintigraphy for detecting bone metastases in prostate cancer: The potential to replace the conventional modality},
journal = {Asian Journal of Urology},
url = {https://www.sciencedirect.com/science/article/pii/S2214388226000822?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...